We use essential cookies and third-party cookies for content.

The National Times - Sales warning slams Ozempic maker Novo Nordisk's stock

Sales warning slams Ozempic maker Novo Nordisk's stock

ECONOMY 04.02.2026
Sales warning slams Ozempic maker Novo Nordisk's stock
Sales warning slams Ozempic maker Novo Nordisk's stock / Photo: © Ritzau Scanpix/AFP

Shares in Danish pharmaceuticals group Novo Nordisk plunged Wednesday after the maker of Ozempic and Wegovy anti-obesity drugs warned of lower sales this year in the key US market.

Change text size:

In afternoon trading the stock was down 18 percent at around 302 kronor ($34) on the Copenhagen stock exchange.

The decline has wiped nearly $32 billion off the market value since Tuesday for Novo Nordisk, one of Europe's biggest companies by capitalisation.

On Tuesday the company said 2025 sales had risen six percent to 309 billion kronor ($48.9 billion), below the eight to 11 percent gain it had forecast as recently as November.

It also said it expected sales to slide by up to 13 percent this year as prices for the popular GLP-1 drugs Ozempic and Wegovy fall in the United States.

"Price reduction in some ways is our investment for the future and for capturing more patients," chief executive Mike Doustdar said while presenting the results.

For Derren Nathan, an analyst at Hargreaves Lansdown, "Donald Trump's crusade on drug prices, patent expiration, and competition all had their part to play."

"Underlying guidance (a new and welcome initiative for the company) was for sales and operating profit to fall 5-13 percent this year, causing the immediate erasing of much of the shares' strong gains so far in 2026," he noted.

The company had nonetheless announced reason to cheer in December when the US Food and Drug Administration (FDA) approved Wegovy to be administered in pill form for weight loss, instead of injections.

Novo Nordisk now expects a similar approval in Europe in the second half of this year.

"The Wegovy pill gives you 16.6 percent weight loss in addition to all the CV [cardiovascular] benefits," Doustdar said.

"This is not just a pill, it's a peptide, it's a large protein inside the pill that gives you that incredible efficacy," he said.

"And that has been giving us a lot of optimism and we will, of course, be pushing this through and promoting it."

L.A.Adams--TNT

Featured

Carney touts Canada 'pivot' away from US as Trump levels new threat

Canadian Prime Minister Mark Carney said Tuesday that reducing economic ties with the United States would come at a cost but the benefits were clear, as President Donald Trump threatened new penalties targeting Canada.

Nearly 1,100 flights cancelled after UK air traffic control glitch

Almost 1,100 flights to and from UK airports were cancelled Tuesday due to what the country's air traffic control service called a technical issue, in the latest glitch to spark travel chaos.

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Change text size: